12:00 AM
 | 
Feb 16, 2015
 |  BC Week In Review  |  Company News  |  Deals

Helsinn, Mundipharma deal

Helsinn granted Mundipharma exclusive, Brazilian commercialization rights to NEPA. The fixed-dose combination of 300 mg netupitant, a...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >